Table 1 Baseline characteristics of IPF patients enrolled into the EMPIRE registry, overall and accoding to time from diagnosis to registry enrollment

Characteristics

n = 1620

n = 1213 (74.9%)

n = 407 (25.1%)

 Austria

26 (1.6)

10 (0.8)

16 (3.9)

 Bulgaria

3 (0.2)

2 (0.2)

1 (0.2)

 Croatia

40 (2.5)

32 (2.6)

8 (2.0)

 Czech Republic

683 (42.2)

591 (48.7)

92 (22.6)

 Hungary

112 (6.9)

89 (7.3)

23 (5.7)

 Israel

78 (4.8)

41 (3.4)

37 (9.1)

 Poland

255 (15.7)

125 (10.3)

130 (31.9)

 Serbia

55 (3.4)

38 (3.1)

17 (4.2)

 Slovakia

110 (6.8)

87 (7.2)

23 (5.7)

 Turkey

258 (15.9)

198 (16.3)

60 (14.7)

Time from diagnosis to enrollment [years], mean (SD)

0.8 (2.0)

0.1 (0.1)

3.1 (3.0)

Duration of symptoms prior to diagnosis [years], mean (SD)

1.6 (2.1)

1.6 (1.8)

1.5 (2.7)

Age at diagnosis [years], mean (SD)

67.6 (8.9)

68.4 (8.6)

65.4 (9.5)

Male sex, n (%)

1157 (71.4)

878 (72.4)

279 (68.6)

BMI [kg/m2], mean (SD)

28.4 (4.4)

28.5 (4.4)

28.1 (4.5)

History of smoking, n (%)

1019 (62.9)

767 (63.2)

252 (61.9)

Familial IPF, n (%)

55 (3.4)

44 (3.6)

11 (2.7)

 Clinical signs

1286 (79.4)

988 (81.5)

298 (73.2)

 Radiological patterns

1590 (98.2)

1194 (98.4)

396 (97.3)

 Histopathological patterns

349 (21.5)

261 (21.5)

88 (21.6)

FEV₁ [% predicted], mean (SD) ^a

86.5 (17.2)

86.4 (16.8)

87.1 (18.2)

FVC [% predicted], mean (SD) ^a

78.7 (19.7)

77.3 (19.4)

82.7 (19.7)

TL_CO [% predicted], mean (SD) ^a

46.3 (20.9)

46.6 (20.6)

45.5 (21.6)

6MWD [m], mean (SD) ^a

388.2 (111.0)

387.7 (109.2)

389.6 (115.8)

 I

772 (47.7)

536 (44.2)

236 (58.0)

 II

710 (43.8)

565 (46.6)

145 (35.6)

 III

138 (8.5)

112 (9.2)

26 (6.4)

 Pharmacological

618 (38.1)

410 (33.8)

208 (51.1)

 Clinical trial

111 (6.9)

53 (4.4)

58 (14.3)

 Rehabilitation

427 (26.4)

352 (29.0)

75 (18.4)

 LTOT

327 (20.2)

218 (18.0)

109 (26.8)